{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Nonsmall+Cell+Lung+Cancer&page=20",
    "query": {
      "condition": "Advanced Nonsmall Cell Lung Cancer",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 1770,
    "total_pages": 177,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Nonsmall+Cell+Lung+Cancer&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Nonsmall+Cell+Lung+Cancer&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T01:35:29.793Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07085091",
      "title": "A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NSCLC (Advanced Non-small Cell Lung Cancer)",
        "HNSCC",
        "CRC (Colorectal Cancer)",
        "ESCC",
        "Colo-rectal Cancer",
        "Head and Neck Cancer",
        "Esophageal Squamous Cell Carcinoma (ESCC)"
      ],
      "interventions": [
        {
          "name": "ALX2004",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ALX Oncology Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2025-08-18",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-11-19T01:35:29.793Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • Santa Monica, California • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07085091"
    },
    {
      "nct_id": "NCT05840510",
      "title": "Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "NSCLC",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Malignant Neoplastic Disease"
      ],
      "interventions": [
        {
          "name": "Adagrasib",
          "type": "DRUG"
        },
        {
          "name": "nab-Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-08-07",
      "completion_date": "2024-12-27",
      "has_results": false,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-11-19T01:35:29.793Z",
      "location_count": 3,
      "location_summary": "Cleveland, Ohio • Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05840510"
    },
    {
      "nct_id": "NCT00050674",
      "title": "Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Filgrastim-SD/01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Schwartzberg, Lee, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2001-11",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2012-12-27",
      "last_synced_at": "2026-11-19T01:35:29.793Z",
      "location_count": 2,
      "location_summary": "Southaven, Mississippi • Memphis, Tennessee",
      "locations": [
        {
          "city": "Southaven",
          "state": "Mississippi"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00050674"
    },
    {
      "nct_id": "NCT00970684",
      "title": "Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Nathan Pennell, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 13,
      "start_date": "2009-09",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2022-08-16",
      "last_synced_at": "2026-11-19T01:35:29.793Z",
      "location_count": 4,
      "location_summary": "Cleveland, Ohio • Mayfield Heights, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Mayfield Heights",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00970684"
    },
    {
      "nct_id": "NCT01063478",
      "title": "Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "RAD001 (in addition to standard radiation and chemotherapy)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 3,
      "start_date": "2010-02",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2014-01-17",
      "last_synced_at": "2026-11-19T01:35:29.793Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01063478"
    },
    {
      "nct_id": "NCT02132325",
      "title": "Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Non-Small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Dignity Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2014-04",
      "completion_date": "2018-02-05",
      "has_results": false,
      "last_update_posted_date": "2018-03-21",
      "last_synced_at": "2026-11-19T01:35:29.793Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02132325"
    },
    {
      "nct_id": "NCT00036790",
      "title": "Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Chronic Myeloproliferative Disorders",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Leukemia",
        "Lung Cancer",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic/Myeloproliferative Diseases",
        "Prostate Cancer",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "motexafin gadolinium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "2002-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-11-19T01:35:29.793Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania • Madison, Wisconsin",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00036790"
    },
    {
      "nct_id": "NCT04383938",
      "title": "Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Gastric Cancer",
        "Non Small Cell Lung Cancer",
        "NSCLC",
        "Urothelial Carcinoma",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "APR-246 (eprenetapopt) + Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aprea Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2020-06-25",
      "completion_date": "2022-04-30",
      "has_results": true,
      "last_update_posted_date": "2025-05-13",
      "last_synced_at": "2026-11-19T01:35:29.793Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04383938"
    },
    {
      "nct_id": "NCT02588612",
      "title": "Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "letetresgene autoleucel (GSK3377794)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2016-02-01",
      "completion_date": "2020-08-10",
      "has_results": true,
      "last_update_posted_date": "2021-09-05",
      "last_synced_at": "2026-11-19T01:35:29.793Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Tampa, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02588612"
    },
    {
      "nct_id": "NCT00017407",
      "title": "Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ISIS 3521",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "2000-10-13",
      "completion_date": "2002-09-09",
      "has_results": false,
      "last_update_posted_date": "2022-12-05",
      "last_synced_at": "2026-11-19T01:35:29.793Z",
      "location_count": 2,
      "location_summary": "Carlsbad, California • Cleveland, Ohio",
      "locations": [
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00017407"
    }
  ]
}